Timpani Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Timpani Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,240	Closed	-$1.27M	–	102
2018 Q4	$1.27M	Sell	10,240 -10,312	-50%	-$1.53M	0.71%	55
2018 Q3	$3.46M	Buy	20,552 +4,491	+28%	+$772K	1%	38
2018 Q2	$2.77M	Buy	+16,061	New	+$2.63M	0.82%	60
2015 Q2	–	Sell	-19,918	Closed	-$3.44M	–	93
2015 Q1	$3.44M	Sell	19,918 -3,961	-17%	-$680K	1.03%	50
2014 Q4	$3.91M	Sell	23,879 -4,696	-16%	-$779K	1.54%	22
2014 Q3	$4.59M	Buy	28,575 +7,473	+35%	+$1.15M	2.1%	9
2014 Q2	$3.1M	Sell	21,102 -6,445	-23%	-$894K	1.39%	31
2014 Q1	$3.82M	Sell	27,547 -3,408	-11%	-$513K	2.02%	14
2013 Q4	$3.92M	Buy	30,955 +2,621	+9%	+$271K	1.95%	12
2013 Q3	$2.61M	Buy	28,334 +4,486	+19%	+$362K	1.54%	25
2013 Q2	$1.64M	Buy	+23,848	New	+$1.46M	1.04%	43

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Timpani Capital Management's JAZZ Position: Q1 2019 in Review

Timpani Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 10,240 shares — an estimated $1.27M sold.

Timpani Capital Management first reported a position in JAZZ in Q2 2013 and held it in 11 quarters. The position peaked at $4.59M in Q3 2014. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Timpani Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Timpani Capital Management sold 10,240 Jazz Pharmaceuticals shares in Q1 2019, an estimated $1.27M.
Timpani Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Timpani Capital Management's Jazz Pharmaceuticals position peaked at $4.59M in Q3 2014.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Timpani Capital Management's 13F filing for Q1 2019, filed 10 May 2019.